Karyopharm Therapeutics enters forbearance agreement and waiver
Karyopharm Therapeutics disclosed it entered a forbearance agreement and waiver effective Sept 10, 2026, in an SEC filing.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.